Skip to Main Content

Paper Details

Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
J Urol
9
2022
Author NameAffiliation
Douglas S ScherrWeill Medical College of Cornell University
Karim Chamieuniversity of california los angeles
  • 1 - 2

Datasets

Release 1.2